biostudies-literatureGrinspoon SKNational Institute of Allergy and Infectious DiseasesNCATS NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesNIDDK NIH HHSNIAID NIH HHSNHLBI NIH HHSNational Heart Lung and Blood Institutee118-e129https://www.ebi.ac.uk/biostudies/studies/S-EPMC11890582biostudies-literatureUnknown12(2)<h4>Background</h4>Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) risk scores used in clinical guidelines perform among people with HIV globally.<h4>Methods</h4>In this prospective cohort study leveraging REPRIEVE data, we included participants aged 40-75 years, with low-to-moderate traditional cardiovascular risk, not taking statin therapy. REPRIEVE participants were enrolled from sites in 12 countries across Global Burden of Disease Study (GBD) regions. We assessed the performance of the pooled cohort equations (PCE) risk score for ASCVD and the data-collection on adverse effects of anti-HIV drugs (D:A:D) risk score. We calculated C statistics, observed-The lancet. HIVPerformance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.PMC11890582P30 AI050410UM1 AI069412UM1 AI106701UL1 TR002384UM1 AI069424UM1 AI068634UM1 AI068636U01 HL123339U01 HL123336U24 HL164284UG3 HL164285UM1 AI069494R01 AI123001P30 DK040561K24 AI157882Kantor AFitch KVAberg JAGardner EBloomfield GSMalvestutto CDUmbleja TChu SMFichtenbaum CJGrinspoon SKCasado JLde la Pena MDouglas PSFantry LEDiggs MRCurrier JSLu MTRibaudo HJTriant VAZanni MVfalsePerformance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.<h4>Background</h4>Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) risk scores used in clinical guidelines perform among people with HIV globally.<h4>Methods</h4>In this prospective cohort study leveraging REPRIEVE data, we included participants aged 40-75 years, with low-to-moderate traditional cardiovascular risk, not taking statin therapy. REPRIEVE participants were enrolled from sites in 12 countries across Global Burden of Disease Study (GBD) regions. We assessed the performance of the pooled cohort equations (PCE) risk score for ASCVD and the data-collection on adverse effects of anti-HIV drugs (D:A:D) risk score. We calculated C statistics, observed-2025-01-01T00:00:00Z2025 Feb2026-06-16T07:18:38.22Z2026-06-16T03:09:40.716ZS-EPMC118905823983251910.1016/s2352-3018(24)00276-510.1016/S2352-3018(24)00276-5